Gateway Celebrity Fight Night Delivers an Unforgettable Evening Directly Funding Early-Phase Cancer Research

Bryan Adams, David Foster, and Others Unite for Fundraiser, with 100% of Money Raised Directly Funding Early-Phase ...

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...
Targeted Oncology

Early Phase Evaluation of Intravesical Erdafitinib in NMIBC

Dr. Antoni Vilaseca Cabo discusses using an intravesical drug delivery system to continuously administer the FGFR inhibitor ...
pharmaphorum

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it ...
Medindia

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Oncology Media Relations   Oncology_media_relations@its.jnj.com     Investor contact: Jess Margevich investor-relations@its.jnj.com ...
Seeking Alpha

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the ...

Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference

Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...
Game Rant

The Most Bizarre Mewgenics Mutations

An HR advisor with a background in recruitment and HRIS functions, with a passion for video games and writing. Oliver grew up playing Call of Duty with his siblings and has garnered 1000s of hours ...